Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.1%

7 terminated/withdrawn out of 99 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

17%

17 trials in Phase 3/4

Results Transparency

21%

13 of 63 completed trials have results

Key Signals

8 recruiting13 with results

Enrollment Performance

Analytics

Phase 2

25(34.7%)

Phase 1

22(30.6%)

Phase 3

14(19.4%)

N/A

8(11.1%)

Phase 4

3(4.2%)

72Total

Phase 2(25)

Phase 1(22)

Phase 3(14)

N/A(8)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (99)

Showing 20 of 99 trials

NCT06844487Phase 3Active Not Recruiting

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT04675931Phase 2Completed

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Role: collaborator

NCT06593080Not ApplicableRecruiting

The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis

Role: collaborator

NCT04752592Not ApplicableCompleted

Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB

Role: collaborator

NCT06958198Phase 1Recruiting

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Role: collaborator

NCT07183371Phase 2Active Not Recruiting

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

Role: collaborator

NCT05357560Phase 1Active Not Recruiting

A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

Role: collaborator

NCT03512249Phase 2Completed

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Role: collaborator

NCT06549257Phase 1Active Not Recruiting

Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

Role: collaborator

NCT06844500Phase 3Active Not Recruiting

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT04300309Phase 2Terminated

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Role: collaborator

NCT06203132Phase 3Recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Role: collaborator

NCT04738812Phase 3Completed

Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

Role: collaborator

NCT04308928Completed

Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis

Role: collaborator

NCT05722184Completed

Diagnostic Evaluation Study of the BactInsight Blood Culture System in West-Africa

Role: collaborator

NCT05220163Not ApplicableActive Not Recruiting

Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19

Role: collaborator

NCT05124691Phase 2Terminated

Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

Role: collaborator

NCT04666311Completed

Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis

Role: collaborator

NCT04342715Active Not Recruiting

A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis

Role: collaborator

NCT03896724Phase 1Completed

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Role: collaborator